Although many TKIs have well-documented cardiotoxic effects, results of a single-center prospective study that assessed effects of 1 year of therapy with imatinib or nilotinib in patients with CML demonstrated safety and efficacy of the 2 agents in this population.
Researchers present findings of a comparison of daily image-guided radiotherapy (IGRT) vs a weekly regimen in patients with N0 localized prostate cancer at the 2018 GU Cancers Symposium.
This observational study demonstrates the significance of using the chemotherapy toxicity risk score (CTRS) to determine if an elderly patient can safely tolerate standard-dose combination chemotherapy, or would fare better with a reduced-dose regimen.
As supportive care improves, elderly patients may benefit from high-dose chemotherapy with autologous stem cell transplantation.
This research aims to assess the correlation between quality of life (QoL) and severity of dermatological toxicity in patients with metastatic colorectal cancer.
Quantity and quality of skeletal muscle is a more accurate measure for determining dose and of potential treatment-related toxicity in patients receiving chemotherapy for early-stage breast cancer.
Researchers report that clinicians may want to start collecting toxicity data routinely and offering early interventions to patients with breast cancer.
Patients with chronic lymphocytic leukemia (CLL) who discontinue TKI therapy due to toxicity can successfully be treated with an alternate TKI.
Treatment with epidermal growth factor receptor tyrosine kinase inhibitors has been linked to earlier paronychia onset and more dermatological visits for skin toxic effects.
This literature review sought to analyze the quality of evidence that supports management practices of cytotoxic drug extravasation.
